Australia markets closed

Veru Inc. (VERU)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6466+0.0367 (+6.02%)
At close: 04:00PM EDT
0.6740 +0.03 (+4.24%)
Pre-market: 05:32AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.6099
Open0.6096
Bid0.6040 x 100
Ask0.6704 x 100
Day's range0.5830 - 0.6467
52-week range0.3600 - 1.5200
Volume2,907,153
Avg. volume1,771,047
Market cap94.65M
Beta (5Y monthly)-0.23
PE ratio (TTM)N/A
EPS (TTM)-1.1000
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend date28 Apr 2014
1y target estN/A
  • GlobeNewswire

    Veru Reschedules Annual Meeting of Shareholders

    --Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings-- MIAMI, FL, March 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that it is rescheduling its 20

  • GlobeNewswire

    Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

    MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced the appointment of Louis Aronne, MD, as Chief Medical Advisor and a member of the Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator

  • GlobeNewswire

    Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

    MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced that it received a delinquency notification letter (“Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) on February 21, 2024 due to the Company’s non-complian